0000905148-24-000063.txt : 20240103 0000905148-24-000063.hdr.sgml : 20240103 20240103192606 ACCESSION NUMBER: 0000905148-24-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231229 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Amado Rafael CENTRAL INDEX KEY: 0001662119 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 24509173 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 4 1 form4.xml X0508 4 2023-12-29 0001704292 Zai Lab Ltd ZLAB 0001662119 Amado Rafael C/O ZAI LAB LIMITED 314 MAIN STREET, 4TH FLOOR, SUITE 100 CAMBRIDGE MA 02142 true See Remarks false American Depositary Shares 2023-12-29 4 M 0 21000 A 21000 D American Depositary Shares 2023-12-29 4 M 0 21000 A 42000 D American Depositary Shares 2024-01-02 4 S 0 19363 26.296 D 22637 D Restricted Share Units 2023-12-29 4 M 0 21000 0 D American Depositary Shares 21000 0 D Restricted Share Units 2023-12-29 4 M 0 21000 0 D American Depositary Shares 21000 84000 D Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer. Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer. This number reflects a net reduction of 126,000 ADSs, which represents Restricted Share Units that were previously reported as aggregated with ADSs in Table I and are now separately reported in Table II. These Restricted Share Units vested in full on 12/30/2023, the first anniversary of the date of grant. Vested shares were delivered to the reporting person following vesting. These Restricted Share Units vest in equal annual installments over five years beginning on 12/30/2023, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting. These ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units. President, Head of Global Oncology Research and Development /s/ Bruce Blefeld, Attorney-in-Fact 2024-01-03